据中国日报报道，12月27日，中核集团在苏州举办核技术医学转化与临床应用大会，并与苏州市联合宣 布：我国首个核医疗示范基地——苏州大学附属第二医院（核工业总医院）浒关院区二期项目正式启 用。核工业总医院浒关二期集核技术精准诊疗、临床试验、医学创新、培训交流功能于一体，聚焦核医 疗及肿瘤、慢病防治等重点方向。 公司方面，据中证报表示，景业智能、中广核技等。 *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 中证报指出，核医疗正迎来政策红利与技术突破的双重催化，随着中国在核素制备、核药研发及核医疗 设备领域的自主化突破，核医疗产业将迎来加速发展。中国核医疗市场预计2025-2030年将保持高速增 长，到"十五五"末，年产值有望达到6000亿元左右。 ...

Core Viewpoint - China Dongfang (01763) reported a revenue of 2.858 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 1.69% [1] - The company's profit attributable to equity shareholders was 172 million RMB, an increase of 11.33% year-on-year, with basic earnings per share of 0.54 RMB [1] - A mid-term dividend of 0.0807 RMB per share is proposed [1] Group Focus - The company focuses on two main industry directions: nuclear medical health and irradiation applications, aiming to provide comprehensive solutions in nuclear medicine and radiation therapy [1] - The business model is structured around a "6+N" industrial layout, which includes six core businesses: radionuclides, radiopharmaceuticals, nuclear medical equipment, overall solutions for nuclear medicine, radiation sources and applications, and irradiation applications [1] Business Operations - The company is engaged in the research, development, manufacturing, and sales of radioactive pharmaceuticals for diagnosis and treatment, as well as medical and industrial radiation source products [1] - It provides services such as irradiation sterilization, material modification, and the design, manufacturing, installation engineering, procurement, and construction (EPC) services of irradiation devices [1] - Additionally, the company offers nuclear medical equipment and construction services for nuclear medicine departments to hospitals and other medical institutions [1]

Group 1 - The company reported a revenue of 2.858 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 1.69% [1] - The profit attributable to equity shareholders was 172 million RMB, an increase of 11.33% year-on-year [1] - The basic earnings per share were 0.54 RMB, and the company proposed an interim dividend of 0.0807 RMB per share [1] Group 2 - The company focuses on two main industry directions: nuclear medical health and irradiation applications, aiming to provide comprehensive solutions in nuclear medicine and radiation therapy [1] - The business model is structured around a "6+N" industrial layout, which includes six core business areas: radionuclides, nuclear pharmaceuticals, nuclear medical equipment, overall solutions for nuclear medicine, radiation sources and applications, and irradiation applications [1] - The company is engaged in the research, development, manufacturing, and sales of radioactive pharmaceuticals for diagnosis and treatment, as well as medical and industrial radiation source products [1]